- Active not recruitingPHASE1
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
This study looks at a new treatment called mRNA-4157, sometimes given with other medicines like pembrolizumab, for different solid cancers. Its main goal is to check how safe it is, how well people tolerate it, and how it affects the body's immune system.
For: Solid TumorsUnited States · Australia · Japan - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).
This study is looking at a new treatment for a type of skin cancer called cutaneous squamous cell carcinoma (cSCC). It combines a new vaccine (mRNA-4157) with an existing drug (pembrolizumab) to see if it works better than standard care for people whose cancer can be removed by surgery.
Italy · Czechia · Romania